A new study reports one of the biggest potential advances against heart failure in more than a decade — a first-of-a-kind, experimental drug that lowered the chances of death or hospitalization by about 20 percent.

Doctors say the Novartis drug — which doesn’t have a name yet — seems like one of those rare, breakthrough therapies that could quickly change care for more than half of the 6 million Americans and 24 million people worldwide with heart failure.

Recommended Stories

DOJ files lawsuit to block results in Alaska Senate race after two Dan Sullivans land on November ballot

Early tallies show black voters turning out in huge numbers in North Carolina

No, Abdul el Sayed, the Second Amendment doesn’t mean muskets only